Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol

Pregnancy, Ovarian Clinical Trial

Official title:
Clinical and Live Birth Rates After Controlled Ovarian Stimulation With the Long Antagonist Protocol Versus Classical Antagonist Protocol

Status Recruiting

Clinical Trial Summary

A randomized prospective study of the evaluation of the clinical IVF results after following Long Antagonist protocol for controlled ovarian stimulation versus following classical antagonist protocol

Clinical Trial Description

A randomized prospective study of administration of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF: Single dose of Degarelix (24mg, 16mg or 12 mg), on day 24th of previous luteal face cycle, was administered. The Clinical Pregnancy and Live Birth Rates were estimated for this group of patients, comparing to the rates of the group which followed classical antagonist protocol. The number of the formed blastocysts in each group is measured, as well. ;

Study Design

Related Conditions & MeSH terms

Pregnancy, Ovarian

Clinical Trial Details

NCT number	NCT03684421
Study type	Observational
Source	Assisting Nature
Contact	Evaggelos Papanikolaou, MD,PhD
Phone	00302310424294
Email	drvagpapanikolaou@yahoo.gr
Status	Recruiting
Phase
Start date	February 15, 2017
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03463278` - The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
Completed	`NCT02442895` - Biomarkers of Ovarian Reserve and Correlation With IVF Treatments	N/A
Completed	`NCT00773825` - Genomic Imprinting and Assisted Reproductive Technologies	N/A
Recruiting	`NCT03693534` - Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol
Recruiting	`NCT03240159` - Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix	Phase 3